VEGFA and macular retinal edema: Randomised controlled trials (RCTs) and real-world studies have identified that anti-VEGF treatments, including Ranibizumab, Bevacizumab and Aflibercept [1–4] impart visual improvement to up to 40% of patients with nAMD, DMO and macular oedema and to about half of patients with myopic CNV [5].